Clinical research of thymosin alpha -1 with glucocorticoid in treatment of HBV -related acute -on -chronic liver failure
10.3760/cma.j.issn.1008-6706.2016.16.017
- VernacularTitle:胸腺法新联合糖皮质激素治疗乙肝相关性慢加急性肝衰竭临床研究
- Author:
Jinmei ZHAN
;
Tianyuan SHI
;
Shaoqing MA
;
Qingdong TONG
;
Jiamin SUN
- Publication Type:Journal Article
- Keywords:
Liver failure,acute;
Thymosin Alpha -1;
Glucocorticoid
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(16):2465-2468
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic effect of thymosin alpha -1 with glucocorticoid in treat-ment of HBV -related hepatic failure.Methods 130 cases were randomly divided into two groups,they were all giv-en antiviral therapy,protect liver,anti -inflammatory,yellow suit the back support,etc.comprehensive treatment;and patients in treatment group were given thymosin alpha -1 with methyl -prednisone intravenously at the early stage of treating process,and then observed the clinic situation and cure rate of those sufferers,The biochemiccal indicator, PTA and blood serum HBV DNA capacity ending with the period of 4 weeks were tested.Results In both groups,the TBil,TC in serum had apparently improved compared with the baseline after the medication,the difference was signifi-cant (t =3.12,P <0.05 and t =3.05,P <0.05).The time of gastrointestinal symptoms improvement and bilirubin subsided time in treatment group were significantly shorter than those of the control group(t =3.34,P <0.01 and t =4.52,P <0.01 ).During the treatment,there was no significant adverse reaction,and there were no differences between two groups in Alt,PTA,HBV DNA,infection,gastrointestinal bleeding,hepatic encephalopathy and hepatore-nal syndrome.The effective rate of treatment group was 75.2%,which was higher than 50.3% of the control group (χ2 =11.02,P <0.01).Conclusion Patients with HBV -related hepatic failure of short -term application of thy-mosin alpha -1 with glucocorticoid treatment,can quickly improve symptoms,greatly improve the efficiency of survival rate,shortem hospitalization period,reduce side effects and enhance security.
